Evidence map›Paper›PMID 41665114›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer.

Shuai Liu, Yongfeng Lao, Long Cheng, Xi Xiao, Longtu Ma, Wenyun Wang, Kun Zhao, Wenxuan Li, Zhongze Zhou, Qingchao Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. [Research Progress on the Role and Mechanisms of PYCR1 
in Tumorigenesis and Progression].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shuai LiuDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Yongfeng LaoDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Long ChengDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Xi XiaoDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Longtu MaDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Wenyun WangDepartment of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Kun ZhaoDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Wenxuan LiDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Zhongze ZhouDepartment of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Qingchao LiDepartment of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Yan TaoInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Shanhui LiuInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Zhilong DongDepartment of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism. It is highly expressed in various cancers and promotes malignant progression, yet its role in DTX resistance in prostate cancer remains unclear. In this study, bioinformatics analyses and

Indexed as

Antineoplastic AgentsDocetaxelEmodinEnzyme InhibitorsMolecular Dynamics SimulationProstatic NeoplasmsPyrroline Carboxylate ReductasesCell Proliferationdelta-1-Pyrroline-5-Carboxylate ReductaseDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorHumansMaleMolecular StructureStructure-Activity RelationshipAntineoplastic Agentsdelta-1-Pyrroline-5-Carboxylate ReductaseDocetaxelEmodinEnzyme InhibitorsPyrroline Carboxylate ReductasesDocetaxelemodinprostate cancerPYCR1virtual screening

Identifiers

PMID41665114
PMCPMC12893152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.